

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2018/045276 A8

(43) International Publication Date
08 March 2018 (08.03.2018)

WIPO | PCT

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/4985 (2006.01)
C07D 471/04 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2017/049834

(22) International Filing Date:

01 September 2017 (01.09.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/382,942 02 September 2016 (02.09.2016) US
62/423,445 17 November 2016 (17.11.2016) US
62/468,598 08 March 2017 (08.03.2017) US
62/482,486 06 April 2017 (06.04.2017) US

(71) Applicant: IRONWOOD PHARMACEUTICALS, INC.
[US/US]; 301 Binney Street, Cambridge, MA 02142 (US).

(72) Inventors: RENNIE, Glen Robert; 46 Elmwood Street #2, Somerville, MA 02144 (US). IYENGAR, Rajesh R.; 23 Stratford Road, West Newton, MA 02465 (US). LEE, Thomas Wai-Ho; 665 Lowell Street, Unit 60, Lexington, MA 02420 (US). NAKAI, Takashi; 7 Gardner Street, Newton, MA 02458 (US). MERMERIAN, Ara; 50 Milton Street, Waltham, MA 02453 (US). JIA, Lei; 4 Jeanette Avenue, Belmont, MA 02478 (US). IM, G-Yoon Jamie; 931 Massachusetts Avenue, Apt. 604, Cambridge, MA 02139 (US). RENHOWE, Paul Allan; 19 Sky View Road, Sudbury, MA 01776 (US). JUNG, Joon; 111 Wendell Road, Newton, MA 02459 (US). GERMANO, Peter; 36 Bontempo Road, Newton, MA 02459 (US). IYER, Karthik; 30 Cambridge Park Drive, Apt. 6121, Cambridge, MA 02140 (US). BARDEN, Timothy Claude; 19 Intervale Road, Salem, MA 01970 (US). TANG, Kim; 256 Slade Street, Belmont, MA 02478 (US).

(74) Agent: DAVIS, Steven G. et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))


(48) Date of publication of this corrected version:

26 April 2018 (26.04.2018)

(15) Information about Correction:

see Notice of 26 April 2018 (26.04.2018)

(54) Title: FUSED BICYCLIC SGC STIMULATORS



(57) Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an up-regulation of the NO pathway is desirable. The compounds are of Formula (I).